Gene therapy for cystic fibrosis is advancing fast. Explore key biotech players, clinical progress, and its potential to ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

Proposals that focus on one or more of the following areas will be prioritized 1: The USDA will provide funding to eligible ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Calley Means is co-piloting Kennedy’s overhaul of HHS and he makes no apologies for sweeping cuts to agency's bureaucracy.

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

Ex-vaccine regulator Peter Marks promoted "ineffective therapy that gave patients false hope, eroded trust in the regulatory ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Shares of early-stage biotech stocks, including Biohaven ( BHVN -6.50%), Recursion Pharmaceuticals ( RXRX -7.37%), and CRISPR ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).